Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

One future project in the lab is to simplify the antibody conjugation protocol that we currently use so ... cell culture that enabled HIF-1α Nobel Prize-winning research. ONI’s LNP Profiler Kit with ...

The second ADC, SGN-CD19A (Seattle Genetics), comprises a humanized anti-CD19 monoclonal antibody conjugated with MMAF using the noncleavable MC, which is the same linker–cytotoxic agent ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Randall ...

where they observed strong T cell and antibody responses that persisted into the memory phase. Finally, the team examined whether DNA-LNP vaccines could be protective in a live SARS-CoV-2 ...